Skip to search formSkip to main contentSkip to account menu

simendan

Known as: ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile, Mesoxalonitrile (+/-)-(P-(1,4,5,6-Tetrahydro-4-Methyl-6-Oxo-3-Pyridazinyl)Phenyl)Hydrazone 
National Institutes of Health

Related topics

Related topics

10 relations

Broader (6)

Anti-Arrhythmia AgentsCardiotonic AgentsHydrazonesPhosphodiesterase Inhibitors

Narrower (4)

LevosimendanOR 1259OR-1855dextrosimendan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Enantiomeric analysis of simendan on polysaccharide-based stationary phases by polar organic solvent chromatography.
Herein, the enantiomeric separation of simendan by HPLC with ultraviolet detection method using polysaccharide-based chiral… 
2019
2019
The efficacy of simendan in the treatment of acute heart failure and its impact on NT-proBNP.
OBJECTIVE Simendan is a calcium sensitizer that enhances myocardial contractility but does not affect ventricular diastole… 
2013
2013
Effect Observation of Simendan combination with Dopamine in Treating the Patients with Chronic Congestive Heart Failure combined with Hypotension
Objective To observe the efficacy and safety of levosimendan combined with dopamine on clinical treatment of chronic congestive… 
2004
2004
Enatiomeric analysis of simendan by CE with beta-CD as chiral selector compared with CMPA-HPLC.
The chiral separation of simendan enantiomers using capillary electrophoresis was studied with beta-cyclodextrin (beta-CD) as… 
1996
1996
Enantiomeric bioanalysis of simendan and levosimendan by chiral high-performance liquid chromatography.
rac-Simendan, (+/-)-(R,S)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-phenyl ] hydrazono]propanedinitrile, and the… 
1994
1994
Hemodynamic effects of the novel cardiotonic drug simendan: Echocardiographic assessment in healthy volunteers
SummarySimendan is a novel cardiotonic drug with mixed properties, including calcium sensitization. Simendan was given… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)